NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

被引:1
|
作者
Wang, Yahui [1 ,2 ]
Liu, Xinyi [1 ]
Zuo, Xianbo [3 ]
Wang, Cuiling [1 ]
Zhang, Zheng [1 ]
Zhang, Haitao [1 ]
Zeng, Tao [4 ]
Chen, Shunqi [1 ]
Liu, Mengyu [1 ]
Chen, Hongxia [1 ]
Song, Qingfeng [5 ]
Li, Qi [1 ,6 ]
Yang, Chenning [1 ]
Le, Yi [7 ]
Xing, Jinliang [8 ]
Zhang, Hongxin [2 ,9 ]
An, Jiaze [10 ]
Jia, Weihua [11 ,12 ]
Kang, Longli [13 ]
Zhang, Hongxing [6 ]
Xie, Hui [14 ]
Ye, Jiazhou [15 ]
Wu, Tianzhun [15 ]
He, Fuchu [2 ]
Zhang, Xuejun [16 ,17 ]
Li, Yuanfeng [1 ]
Zhou, Gangqiao [1 ,18 ]
机构
[1] Beijing Inst Radiat Med, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[2] Beijing Inst Lifeom, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Dermatol, Dept Pharm, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Fac Hepatobiliary Pancreat Surg, Med Ctr 1, Beijing, Peoples R China
[5] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[6] Univ South China, Sch Med, Dept Neurosci, Hengyang, Hunan, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 5, Beijing, Peoples R China
[8] Air Force Med Univ, Expt Teaching Ctr Basic Med, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China
[9] Air Force Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China
[10] Air Force Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
[11] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China
[12] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[13] Xizang Minzu Univ, Sch Med, Key Lab Mol Genet Mech & Intervent Res High Altitu, Key Lab High Altitude Environm & Genes Related Dis, Xianyang, Shaanxi, Peoples R China
[14] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Oncol, Med Ctr 5, Beijing, Peoples R China
[15] Guangxi Med Univ, Guangxi Liver Canc Diag & Treatment Engn & Technol, Dept Hepatobiliary & Pancreat Surg, Canc Hosp, Nanning, Guangxi, Peoples R China
[16] Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Anhui, Peoples R China
[17] Anhui Med Univ, Affiliated Hosp 1, Inst Dermatol, Hefei, Anhui, Peoples R China
[18] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源
CELL GENOMICS | 2024年 / 4卷 / 05期
基金
中国国家自然科学基金;
关键词
GENOME-WIDE ASSOCIATION; DNA-REPAIR; SUSCEPTIBILITY LOCUS; READ ALIGNMENT; CANCER; EXPRESSION; NBS1; PATHOGENICITY; POLYMORPHISM; FRAMEWORK;
D O I
10.1016/j.xgen.2024.100550
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To identify novel susceptibility genes for hepatocellular carcinoma (HCC), we performed a rare -variant association study in Chinese populations consisting of 2,750 cases and 4,153 controls. We identified four HCCassociated genes, including NRDE2 , RANBP17 , RTEL1 , and STEAP3 . Using NRDE2 (index rs199890497 [p.N377I], p = 1.19 3 10 - 9 ) as an exemplary candidate, we demonstrated that it promotes homologous recombination (HR) repair and suppresses HCC. Mechanistically, NRDE2 binds to the subunits of casein kinase 2 (CK2) and facilitates the assembly and activity of the CK2 holoenzyme. This NRDE2-mediated enhancement of CK2 activity increases the phosphorylation of MDC1 and then facilitates the HR repair. These functions are eliminated almost completely by the NRDE2-p.N377I variant, which sensitizes the HCC cells to poly(ADP-ribose) polymerase (PARP) inhibitors, especially when combined with chemotherapy. Collectively, our findings highlight the relevance of the rare variants to genetic susceptibility to HCC, which would be helpful for the precise treatment of this malignancy.
引用
收藏
页数:34
相关论文
共 50 条
  • [31] SLFN11 regulates the sensitivity to PARP inhibitors in RCC regardless of homologous recombination deficiency
    Okuda, Yohei
    Kato, Taigo
    Takashima, Tsuyoshi
    Kanaki, Tomohiro
    Liu, Yutong
    Yoshimura, Akihiro
    Tani, Masaru
    Oka, Toshiki
    Yamamichi, Gaku
    Ishizuya, Yu
    Hayashi, Takuji
    Yamamoto, Yoshiyuki
    Hatano, Koji
    Kawashima, Atsunari
    Murai, Junko
    Nonomura, Norio
    CANCER SCIENCE, 2025, 116 : 1660 - 1660
  • [32] Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
    Ádám Póti
    Hella Gyergyák
    Eszter Németh
    Orsolya Rusz
    Szilárd Tóth
    Csenger Kovácsházi
    Dan Chen
    Bernadett Szikriszt
    Sándor Spisák
    Shunichi Takeda
    Gergely Szakács
    Zoltan Szallasi
    Andrea L. Richardson
    Dávid Szüts
    Genome Biology, 20
  • [33] Deciphering the role of homologous recombination deficiency mutations in the response to combined immune checkpoint and PARP inhibitors
    Chaudhuri, Sibapriya
    Thomas, Scott
    Timmerman, Luika
    Munster, Pamela
    CANCER RESEARCH, 2024, 84 (03)
  • [34] New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors
    Fong W. Liu
    Krishnansu S. Tewari
    Current Treatment Options in Oncology, 2016, 17
  • [35] Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors.
    Campoverde, Leticia
    Da Silva, Laercio Lopes
    Silveira, Hyan
    Nogueira, Wilson Coelho
    Mina, Lida A.
    Lopes, Gilberto
    Batalini, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17615 - E17615
  • [36] New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors
    Liu, Fong W.
    Tewari, Krishnansu S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (03)
  • [37] Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
    Poti, Adam
    Gyergyak, Hella
    Nemeth, Eszter
    Rusz, Orsolya
    Toth, Szilard
    Kovacshazi, Csenger
    Chen, Dan
    Szikriszt, Bernadett
    Spisak, Sandor
    Takeda, Shunichi
    Szakacs, Gergely
    Szallasi, Zoltan
    Richardson, Andrea L.
    Szuets, David
    GENOME BIOLOGY, 2019, 20 (01)
  • [38] The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
    Yayun Gu
    Cheng Wang
    Rongxuan Zhu
    Jianshui Yang
    Wenwen Yuan
    Yanhui Zhu
    Yan Zhou
    Na Qin
    Hongbing Shen
    Hongxia Ma
    Hongxia Wang
    Xiaoan Liu
    Zhibin Hu
    Cancer Biology & Medicine, 2021, 18 (01) : 74 - 92
  • [39] The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
    Yayun Gu
    Cheng Wang
    Rongxuan Zhu
    Jianshui Yang
    Wenwen Yuan
    Yanhui Zhu
    Yan Zhou
    Na Qin
    Hongbing Shen
    Hongxia Ma
    Hongxia Wang
    Xiaoan Liu
    Zhibin Hu
    Cancer Biology & Medicine , 2021, (01) : 74 - 92
  • [40] The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
    Gu, Yayun
    Wang, Cheng
    Zhu, Rongxuan
    Yang, Jianshui
    Yuan, Wenwen
    Zhu, Yanhui
    Zhou, Yan
    Qin, Na
    Shen, Hongbing
    Ma, Hongxia
    Wang, Hongxia
    Liu, Xiaoan
    Hu, Zhibin
    CANCER BIOLOGY & MEDICINE, 2021, 18 (01) : 74 - +